EDEleanor Dixon

Eleanor Dixon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eleanor Dixon has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Adverse drug reactions, particularly liver disorders, drive interruptions in anti‐tuberculosis treatment: A retrospective cohort study

    by Eleanor G. Dixon, Evita Biraua, Edvards Brencsēns, Vitālijs Pašuks, Vija Riekstina, Anete Šperberga, Marisa D. Muckian, James W. Dear, Liga Kuksa, Derek J. Sloan, et al.

    Aims: Adverse drug reactions (ADRs) are a key driver of missed doses of anti‐tuberculosis (TB) therapy. We aimed to determine the relative burden of ADR‐driven missed doses, the missed dose patterns associated with ADRs, and the association between specific ADRs and missed doses. Methods: In this retrospective cohort study, adults (≥18 years) who began the standard 6‐month drug‐sensitive anti‐TB regimen in an outpatient facility in Riga, Latvia (May 2015–September 2022) and missed at least one dose of treatment were included. Data were collected from medical records and observed therapy records. Missed doses were subdivided into early discontinuation or sporadically missed. Descriptive analyses and lasagne plots were used. Results: Across 174 patients, 54 (31.0%, CI: 24.2–37.9%) missed doses due to ADRs. Of 31 320 doses, 4217 (13.5%, CI: 13.1–13.9%) were missed, 20.9% (880/4217, CI: 19.6–22.1%) were due to ADRs. Eighteen (10.3%) of the 174 patients discontinued treatment early, two of which (11.1%) were due to ADRs. Doses missed due to ADRs caused longer yet less frequent periods of sporadic missed doses: 56.4% (479/849) of sporadic missed doses were 1 day in length vs . only 9.1% (7/77) for ADR‐related ones. Hepatobiliary disorders were the leading ADR group causing missed doses. Hepatobiliary ADRs caused long median durations of missed doses (median 15.0, CI: 13.0–22.0). Conclusion: Our study underscores the importance of ADRs as a cause of missed doses of treatment, particularly hepatobiliary disorders. Regimens that are less prone to ADRs and strong healthcare system support structures for patients with ADRs are required to minimize missed doses, reducing unfavourable outcomes.

  • Open Access

    Adverse drug reactions, particularly liver disorders, drive prolonged interruptions in anti-tuberculosis treatment: a retrospective cohort study

    by Eleanor Dixon, Evita Biraua, Edvards Brencsēns, Vitālijs Pašuks, Vija Riekstina, Anete Šperberga, Marisa Muckian, James Dear, Liga Kuksa, Derek Sloan, et al.

    Aim: Adverse drug reactions (ADRs) are a key driver of missed doses of anti-tuberculosis (TB) therapy. We aimed to determine the relative burden of ADR-driven missed doses, the missed dose patterns associated with ADRs, and the association between specific ADRs and missed doses. Methods: In this retrospective cohort study, adults (≥18 years) who began the standard six-month drug-sensitive anti-TB regimen in an outpatient facility in Riga, Latvia (May 2015–September 2022) and missed at least one dose of treatment were included. Data were collected from medical records and observed therapy records. Missed doses were subdivided into early discontinuation or sporadically missed. Descriptive analyses and lasagne plots were used Results: Across 174 patients, 31.0% (54) missed doses due to ADRs. 4,217/31,320 (13.5%) of doses were missed- 20.9% (880/4,217) were due to ADRs. 18/174 (10.3%) patients discontinued treatment early, 2/18 (11.1%) due to ADRs. Doses missed due to ADRs caused longer yet less frequent periods of sporadic missed doses: 56.4% (479/849) of sporadic missed doses were one day in length versus only 9.1% (7/77) for ADR-related ones. Hepatobiliary disorders were the leading ADR group causing missed doses. Metabolism and nutrition and hepatobiliary ADRs caused the longest median durations of missed doses. Conclusion: Our study underscores the importance of ADRs as a cause of missed doses of treatment, particularly hepatobiliary disorders. Regimens that are less prone to ADRs and strong healthcare system support structures for patients with ADRs are required to minimise missed doses, reducing unfavourable outcomes.

  • Open Access

    No action is without its side effects: Adverse drug reactions and missed doses of antituberculosis therapy, a scoping review

    by Eleanor G. Dixon, Shaista Rasool, Brian Otaalo, Ashmika Motee, James W. Dear, Derek Sloan, Helen R. Stagg

    Aims: A key reason for the failure of antituberculosis (anti‐TB) treatment is missed doses (instances where medication is not taken). Adverse drug reactions (ADRs) are 1 cause of missed doses, but the global evidence, their relative contribution to missed doses vs. other causes, the patterns of missed doses due to ADRs and the specific ADRs associated with missed doses have not been appraised. We sought to address these questions through a scoping review.Methods: MEDLINE, Embase and Web of Science were searched on 3 November 2021 using terms around active TB, missed doses and treatment challenges. Studies reporting both ADR and missed dose data were examined (PROSPERO: CRD42022295209).Results: Searches identified 108 eligible studies: 88/108 (81%) studies associated ADRs with an increase in missed doses; 33/61 (54%) studies documenting the reasons for missed doses gave ADRs as a primary reason. No studies examined patterns of missed doses due to ADRs; 41/108 (38%) studies examined associations between 68 types of ADR (across 15 organ systems) and missed doses. Nuance around ADR‐missed doses relations regarding drug susceptibility testing profile and whether the missed doses originated from the patient, healthcare professionals, or both were found.Conclusion: There is extensive evidence that ADRs are a key driver for missed doses of anti‐TB treatment. Some papers examined specific ADRs and none evaluated the patterns of missed doses due to ADRs, demonstrating a knowledge deficit. Knowing why doses both are and are not missed is essential in providing targeted interventions to improve treatment outcomes.


  • Open Access

    No action is without its side effects: adverse drug reactions and missed doses of anti-tuberculosis therapy, a scoping review

    by Eleanor Dixon, Shaista Rasool, Brian Otaalo, Ashmika Motee, James Dear, Derek Sloan, Helen Stagg

    Introduction: A key reason for the failure of anti-tuberculosis (TB) treatment is missed doses (instances where medication is not taken). Adverse drug reactions (ADRs) are one cause of missed doses, but the global evidence for this, their relative contribution to missed doses versus other causes, the patterns of missed doses due to ADRs, and the specific ADRs associated with missed doses have not been appraised. We sought to address these questions through a scoping review. Methods: MEDLINE, Embase and Web of Science were searched on 3 November 2021 using terms around active TB, missed doses and treatment challenges. Studies reporting both ADR and missed dose data were examined. (PROSPERO: CRD42022295209). Results: Searches identified 108 eligible studies. 88/108 (81%) studies associated ADRs with an increase in missed doses. 33/61 (54%) studies documenting the reasons for missed doses gave ADRs as a primary reason. No studies examined patterns of missed doses due to ADRs. 41/108 (38%) studies examined associations between 68 types of ADR (across 15 organ systems) and missed doses. Nuance around ADR-missed doses relations regarding drug susceptibility testing profile and missed dose originator was found. Conclusions: There is extensive evidence that ADRs are a key driver for missed doses of anti-TB treatment. Some papers examined specific ADRs, none evaluated the patterns of missed doses due to ADRs, demonstrating a knowledge deficit. Knowing why doses both are and are not missed due to ADRs is essential in providing targeted interventions to improve treatment outcomes.

  • Open Access

    Deprescribing montelukast in children with asthma: a systematic review

    by Eleanor Grace Dixon, Charlotte King, Andrew Lilley, Ian P Sinha, Daniel B Hawcutt

    Background National and international asthma guidelines recommend adjusting asthma treatment based on levels of control, yet no guidance is given regarding the stepping-down of montelukast in children and young people (CYP). Objective To systematically review evidence regarding deprescribing montelukast in CYP with established asthma. Design Systematic review. Data sources Embase, Medline, PubMed and CINAHL were searched up to October 2020. Study selection Eligible studies contained patients aged 0–18 years with a diagnosis of asthma, who had been administering montelukast before it was withdrawn. All reasons for withdrawal were included. Results The search identified 197 papers. After deduplication, five papers were included (three randomised control studies and two cohort studies). Four studies observed the impact of montelukast withdrawal for 2 weeks, and one study for 8 weeks. The impact of withdrawal was measured in the studies using a combination of lung tests (eg, forced expiratory volume in 1 s (FEV1), fractional exhaled nitric oxide (FeNO)), asthma scoring methods and exercise challenges. Of the 17 domains in the Core Outcome Set for Clinical Trials in Childhood Asthma, eight outcomes were measured in at least one of the five studies, with all five studies measuring the outcome of ‘Lung Function’. No significant differences were found between the montelukast and placebo groups following montelukast withdrawal. Significant differences between the comparator points within the test group were found in nine outcomes across four studies; FEV1/forced vital capacity, FEV1, forced expiratory flows (25%–75%), asthma score (study specific), maximum % fall in FEV1 and time to recovery (post exercise) significantly decreased whereas FEV1/bronchodilator response, FeNO and eNO significantly increased. Conclusion Only limited, contradictory and short-term effects of deprescribing montelukast in CYP with established asthma are presented in literature. Definitive studies determining clinical stability, and impact of deprescribing montelukast in CYP are imperative to improve the safety of asthma treatment in CYP. PROSPERO registration number CRD42020213971.


  • Open Access

    Adverse drug reactions of leukotriene receptor antagonists in children with asthma: a systematic review

    by Eleanor Grace Dixon, Charlotte Em Rugg-Gunn, Vanessa Sellick, Ian P Sinha, Daniel B Hawcutt

    Background Asthma is the most common chronic condition of childhood. Leukotriene receptor antagonists (LTRAs) are included in international guidelines for children and young people (CYP), but there have been highly publicised concerns about potential adverse effects. The aim was to identify and understand the reported frequency of adverse drug reactions (ADRs) attributed to LTRAs in CYP with asthma. Methods Embase, MEDLINE, PubMed and CINAHL were searched up to October 2020. Reference lists of eligible papers were manually screened. Eligible studies identified adverse events attributed to an LTRA in individuals aged between 0 and 18 years diagnosed with asthma. Four different tools were used to assess risk of bias or quality of data to accommodate the papers assessed. Results The search identified 427 papers after deduplication; 15 were included (7 case reports, 7 case–controlled or cohort studies and 1 randomised control trial (RCT)). 7012 patients were recorded, of which 6853 received an LTRA. 13 papers examined the ADRs attributed to montelukast, one to pranlukast and one to unspecified LTRAs. After language standardisation, 48 ADRs were found, 20 of which were psychiatric disorders. Across all studies, the most commonly reported ADRs were ‘anxiety’, ‘sleep disorders’ and ‘mood disorders’. The frequency of ADRs could be calculated in seven of the eight studies. Applying standardised frequency terms to the prospective studies and RCT, there were 14 ‘common’ and ‘uncommon’ ADRs. ‘Common’ ADRs included ‘agitation/hyperactivity/irritability/nervousness’, ‘aggression’ and ‘headache’. The case reports showed a similar pattern, describing 46 different ADRs experienced by a total of eight patients. Conclusions LTRAs have a wide range of suspected ADRs in CYP, predominantly gastrointestinal and neuropsychiatric disorders. Careful monitoring of CYP with asthma is required, both to assess and manage ADRs and to step treatment down when clinically stable. PROSPERO registration number CRD42020209627.


  • Deprescribing montelukast in children with asthma: a systematic review

    by Eleanor Dixon, Charlotte King, Daniel Hawcutt, Ian Sinha

    Background: National and international asthma guidelines recommend adjusting asthma treatment based upon the asthma control of patients, yet no guidance is given regarding the stepping-down of montelukast in children and young people (CYP). Aim: To systematically review current understanding regarding deprescribing montelukast in children and adolescents with established asthma. Method: Searches of Medline, PubMed, EMBASE and CINAHL were undertaken (September 2020) for reports regarding deprescribing montelukast in CYP with established asthma since 1998 (drug licenced). Eligible studies were assessed for risk of bias using appropriate risk assessment tools. Results: The search identified 197 papers after deduplication; 3 randomised control studies and 2 cohort studies met the eligibility criteria. 4 studies observed the impact of montelukast withdrawal for 2 weeks and 1 for 8 weeks. Impact of withdrawal was measured using a combination of lung function tests (e.g. FEV1, FeNO), asthma score systems and exercise challenges. 9 of the 18 impact measures demonstrated a significant change between the end of treatment and the end of the washout period. Of these, 5 demonstrated reduced pulmonary function, 1 a worsening of asthma control, 2 showed an increase in pulmonary function and 1 an increase in asthma control. A mean of 2.8 out of 17 factors outlined by the Core Outcome Set (COS) for clinical trials in childhood asthma were measured per study. Conclusion: Only limited, contradictory and short-term effects of deprescribing montelukast are present in literature. Further studies examining deprescribing montelukast on the COS for clinical trials in childhood asthma are imperative.

  • Adverse drug reactions of leukotriene receptor antagonists in children with asthma: a systematic review

    by Eleanor Dixon, Charlotte Rugg-Gunn, Ian Sinha, Daniel Hawcutt

    Background: There is increasing awareness of the adverse drug reactions (ADRs) to leukotriene receptor antagonists (LTRAs) in children and young people (CYP) with asthma, but these have not been systematically reviewed. Aim: To systematically review reported ADRs attributed to LTRAs in children and adolescents with established asthma. Method: Searches of Medline, PubMed, EMBASE and CINAHL were undertaken (September 2020) for suspected ADRs attributed to LTRAs in CYP with established asthma since 1998 (licencing of originator drug in the class). Eligible studies were assessed for risk of bias using appropriate risk assessment tools. Results: The search identified 427 papers after deduplication; 7 case reports, 5 case-controlled or cohort studies, 2 non-comparative studies and 1 randomised control study met the eligibility criteria. 14 studies examined montelukast and 1 pranlukast. After language standardisation, 48 ADRs were found, 20 of which were psychiatric disorders. Applying standardised frequency terms, the ‘very common’ and ‘common’ ADRs reported in the studies were hepatobiliary disorders (18%), psychiatric disorders (7.5%), social circumstance (e.g. declining school performance) (3.6%), nervous system disorders (1.8%) and gastrointestinal disorders (1.3%). Data from the 7 case reports identified 46 severe LTRA-induced ADRs. Overall, the most commonly reported ADRs included anxiety, sleep disorders and mood disorders. Conclusion: LTRAs in CYP generate a significant number of ADRs in children with asthma, and clinicians need to be vigilant for these in clinical practice.